Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2005 Oct;37(5):290-3. doi: 10.4143/crt.2005.37.5.290. Epub 2005 Oct 31.
This study compared the WHO criteria with the response evaluation criteria in solid tumors (RECIST) in the same patients with metastatic colorectal cancer in order to determine the significance of the RECIST. In addition, this study compared the estimations of medical oncologists with those of a radiologist.
Between 2002 and 2005, a total of 48 patients (male: female ratio, 29:19; median age, 58 years) with measurable lesions receiving chemotherapy for metastatic colorectal carcinoma were enrolled in this study. Two medical oncologists and one radiologist, who were blinded to the patients' condition, independently reviewed all the CT images. The results were compared using a kappa test.
The kappa test for concordance between the WHO and RECIST criteria of the medical oncologists and the radiologist were 0.908 and 0.841, respectively. The level of concordance between the investigators using the WHO and RECIST were 0.722 and 0.753, respectively.
The RECIST criteria are comparable to the WHO criteria in evaluating the response of colorectal carcinoma, but have simple and reproducible guidelines. The use of RECIST is recommended for evaluating the treatment efficacy in clinical trials and practice.
本研究旨在比较转移性结直肠癌患者采用世界卫生组织（WHO）标准与实体瘤疗效评价标准（RECIST）的结果，以确定 RECIST 的意义。此外，本研究还比较了医学肿瘤学家和放射科医生的评估结果。
在 2002 年至 2005 年间，共纳入了 48 例接受化疗治疗转移性结直肠癌的可测量病变患者（男/女比例，29/19；中位年龄，58 岁）。两名医学肿瘤学家和一名放射科医生在不了解患者病情的情况下，独立审查了所有 CT 图像。使用 Kappa 检验比较结果。
医学肿瘤学家和放射科医生对 WHO 和 RECIST 标准的一致性 Kappa 检验分别为 0.908 和 0.841。使用 WHO 和 RECIST 标准的研究者之间的一致性水平分别为 0.722 和 0.753。
RECIST 标准在评估结直肠癌的反应方面与 WHO 标准相当，但具有简单且可重复的指南。建议在临床试验和实践中使用 RECIST 来评估治疗效果。
